

# Paul Kostenuik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10811252/publications.pdf>

Version: 2024-02-01

20  
papers

1,828  
citations

430874

18  
h-index

839539

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

2573  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. <i>Bone</i> , 2006, 39, 754-766.	2.9	398
2	Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5056-5062.	3.6	234
3	Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.. <i>Current Pharmaceutical Design</i> , 2001, 7, 613-635.	1.9	205
4	Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis. <i>American Journal of Pathology</i> , 2004, 164, 543-555.	3.8	130
5	Fracture healing physiology and the quest for therapies for delayed healing and nonunion. <i>Journal of Orthopaedic Research</i> , 2017, 35, 213-223.	2.3	128
6	RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 843-854.	2.8	81
7	RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF $\alpha$ or anti-IL-1 therapies. <i>Arthritis Research and Therapy</i> , 2009, 11, R187.	3.5	75
8	RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 1946-1954.	2.8	70
9	The Evolving Systemic and Local Biomarker Milieu at Different Stages of Disease Progression in Rat Adjuvant-Induced Arthritis. <i>Journal of Clinical Immunology</i> , 2009, 29, 158-174.	3.8	69
10	Tumor necrosis factor $\alpha$ and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2644-2654.	6.7	68
11	Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses. <i>Journal of Immunology</i> , 2007, 179, 7497-7505.	0.8	62
12	Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1158-1169.	2.8	61
13	Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. <i>Arthritis and Rheumatism</i> , 2005, 52, 1604-1611.	6.7	58
14	OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1627-1640.	2.8	57
15	Osteopetrosis rescue upon RANKL administration to Rankl <sup>-/-</sup> mice: A new therapy for human RANKL-dependent ARO. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2501-2510.	2.8	44
16	Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. <i>Bone</i> , 2012, 50, 628-637.	2.9	34
17	Osteoprotegerin Abrogated Cortical Porosity and Bone Marrow Fibrosis in a Mouse Model of Constitutive Activation of the PTH/PTHrP Receptor. <i>American Journal of Pathology</i> , 2009, 174, 2160-2171.	3.8	29
18	Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants. <i>Tissue Engineering - Part A</i> , 2018, 24, 1672-1679.	3.1	20

#	ARTICLE	IF	CITATIONS
19	On the Evolution and Contemporary Roles of Bone Remodeling. , 2013, , 873-914.		4
20	On the evolution and contemporary roles of bone remodeling. , 2021, , 727-772.		1